Departed
Nelson Cabatuan
Chief Financial Officer
LEXX ·
Lexaria Bioscience Corp.
replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024
Ready 8-Ks
50
Latest filing
February 6, 2026, 6:59 PM ET
Top materiality
0.75
Event mix
other_material ×35 · leadership ×7 · regulatory ×5
Sentiment
13 pos · 4 neg · 33 neu
Executive change
recent →
Recent 8-K filings for LEXX
Highest-materiality recent filing
Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37
- Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.
- Warrants for 2,666,667 shares at $1.37, immediately exercisable, 5-year term from resale registration.
-
Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure
Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).
-
Lexaria Bioscience shareholders elect all director nominees, ratify auditors at annual meeting
All seven director nominees elected: highest vote % John Docherty (96.4%), lowest Albert Reese Jr. (73.6%).
-
Lexaria raises $3.5M in registered direct offering with warrants
Issued 2,661,600 shares at $1.315/share, gross proceeds ~$3.5M.
-
Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37
Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.
-
Lexaria Bioscience terminates $5M equity distribution agreement with JonesTrading
Terminated Capital on Demand Sales Agreement with JonesTrading effective September 19, 2025.
-
Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm
Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.
-
Lexaria raises $2M via registered direct offering of common stock and pre-funded warrants
Gross proceeds $2M from sale of 2M shares/pre-funded warrants at $1.00 per share to one institutional investor.
-
Lexaria reduces at-the-market equity facility from $20M to $5M
Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.
-
Lexaria shareholders re-elect all directors; McKechnie gets 54% support, Baxter 62%
Annual meeting on Jan 14, 2025: 9,761,279 shares (55.93% of outstanding) represented.
-
New agreement effective Jan 1, 2025, replaces prior 2022 pact; Docherty remains President and Chief Scientific Officer.
-
Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial
Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.
-
Lexaria Bioscience sets Jan 14, 2025 annual/special meeting; director nomination deadline Nov 25
Joint Annual and Special Meeting scheduled for January 14, 2025.
-
Lexaria raises $5M via registered direct offering and private placement of warrants
Gross proceeds of $5.0M from sale of 1,633,987 shares at $3.06/share plus 4,551,019 warrants exercisable at $3.06.
-
Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024
Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.
-
Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman
Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.
-
Lexaria Bioscience enters $20M at-the-market equity sales agreement with JonesTrading
Up to $20M of common stock may be sold from time to time through Agent JonesTrading as ATM offering.
-
CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.
-
Lexaria exercises warrants for ~$4.4M, issues new warrants with $4.75 strike
Existing investor exercises 2,917,032 warrants for ~$4.4M; gross proceeds ~$4.7M including new warrant consideration.
-
Lexaria Bioscience shareholders elect all six directors and ratify auditor at annual meeting
All six director nominees elected with 85-99% support: Bunka, Docherty, Baxter, McKechnie, Reese Jr., Turkel.
-
Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity
Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.
-
Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024
Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.
-
Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1
FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.
-
Lexaria raises $3.6M in registered direct offering and private placement
Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.
-
Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD
Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.
-
Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.
-
Lexaria's DehydraTECH semaglutide outperforms Rybelsus in human pilot study
DehydraTECH semaglutide showed 43% higher peak blood levels vs Rybelsus; levels higher at all 19 time points.
-
Lexaria Bioscience regains Nasdaq bid price compliance; warrant exercises yield $444,895
Received Nasdaq letter on Nov 3, 2023 confirming cure of $1.00 minimum bid price deficiency after 11 consecutive days above $1.00 (Oct 19 - Nov 2).
-
Lexaria receives Nasdaq bid price deficiency notice; 180-day cure until April 15, 2024
Received Nasdaq notice on Oct 17, 2023 for failing to maintain $1.00 minimum bid price for continued listing on Nasdaq Capital Market.
-
Up-front cash payment received; minimum future payments and ongoing royalties agreed.
-
Lexaria shareholders approve reverse stock split; company granted two Canadian patents
Shareholders approved reverse stock split with ratio between 2:1 and 12:1 (67% for).
-
Lexaria raises $1.57M in registered direct offering and private placement
Gross proceeds of $1.57M from sale of 889,272 shares at $0.97, pre-funded warrants for 729,058 shares at $0.9699, and private placement warrants for 1,618,330 shares at $0.97.
-
Lexaria regains Nasdaq minimum bid price compliance; plans reverse split meeting
Received Nasdaq letter confirming bid price >=$1.00 for 10 consecutive days through Aug 23, 2023.
-
New wholly-owned subsidiary Lexaria Nutraceutical Corp. receives exclusive perpetual license for DehydraTECH in consumer packaged goods (excluding cannabis/nicotine).
-
Lexaria granted three US patents for DehydraTECH in hypertension and nicotine delivery
Issued US Patents #11,666,543 and #11,666,544 for DehydraTECH in treating hypertension.
-
Lexaria receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Nasdaq letter dated June 22, 2023 cites LEXX not meeting $1.00 bid price requirement.
-
Lexaria Bioscience dismisses CFO Gregory Downey; CEO assumes principal financial officer role
Gregory Downey dismissed as CFO effective June 6, 2023; company actively seeking replacement.
-
Lexaria engages InClin as CRO for Phase 1b hypertension study; budget $1.4M
Master Services Agreement with InClin for FDA-registered Phase 1b hypertension study HYPER-H23-1 using DehydraTECH-powered cannabidiol.
-
All six director nominees elected: Bunka (96.5%), Docherty (96.3%), Baxter (74.3%), McKechnie (95.7%), Reese (96.2%), Turkel (97.6%).
-
Lexaria Bioscience prices public offering of 2.1M units at $0.95/unit for $2.0M gross proceeds
2,106,000 units priced at $0.95 each, each unit comprising one share of common stock and one warrant.
-
7% body weight loss maintained over 8 weeks in obese diabetic Zucker rats dosed with DehydraTECH-CBD.
-
Lexaria Bioscience hires former GW Pharma USA President Julian Gangolli as Strategic Advisor
Julian Gangolli, former President of GW Pharmaceuticals USA, appointed as Strategic Advisor.
-
Lexaria CEO letter details FDA pre-IND success, new Japan client, no 2022 equity raise
FDA pre-IND meeting cleared path toward formal IND filing for DehydraTECH-CBD hypertension program; Phase 1(b) study expected in 2023.
-
Pilot study: at 50 mg/kg, only DehydraTECH-CBD showed seizure reduction; at 75 mg/kg, full elimination in 66.6% of animals vs. 50% for Epidiolex.
-
Lexaria Bioscience replaces auditor; Davidson declines re-election, MaloneBailey appointed
Davidson & Company LLP will not stand for re-election after completing FY2022 audit.
-
Lexaria's DehydraTECH-CBD lowers blood pressure in 66-patient hypertension study
Systolic BP reduced up to 5.60 mmHg (p<0.001) over 5 weeks vs. placebo; no serious adverse events.
-
Lexaria Bioscience appoints Catherine Turkel to board; grants stock options, receives Mexican patent
Appointed Catherine Turkel, PharmD, PhD as independent director; board expanded to six members effective Sept 2, 2022.
-
Lexaria receives positive FDA pre-IND response for DehydraTECH-CBD hypertension program
FDA agreed to 505(b)(2) NDA pathway, typically enabling faster commercial approval.
-
Lexaria enters $5.925M at-the-market equity distribution agreement with Maxim Group
Aggregate offering price of up to $5,925,000 of common stock through Maxim Group as distribution agent.
-
Lexaria enters manufacturing and license agreements with BevNology for DehydraTECH CBD tech
Manufacturing operating agreement for fee-based production of DehydraTECH-enabled APIs for corporate clients.
-
Lexaria licenses DehydraTECH to AnodGen; pre-IND filed for CBD hypertension
Lexaria subsidiary entered 5-year non-exclusive license with AnodGen for DehydraTECH in Europe, UK, Australia, NZ.
Executive changes
Role change
(interim)
Richard Christopher
principal financial officer (interim)
LEXX ·
Lexaria Bioscience Corp.
Richard Christopher, the Company’s Chief Executive Officer who assumed the responsibilities as the Company’s principal financial officer on an interim basis, relinquished those responsibilities to Mr. Shankman.
Appointed
Michael Shankman
Chief Financial Officer
LEXX ·
Lexaria Bioscience Corp.
Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.
Appointed
Richard Christopher
Chief Executive Officer
LEXX ·
Lexaria Bioscience Corp.
appointed Richard Christopher, age 54, to the position of Chief Executive Officer
Role change
Christopher Bunka
Chairman of the Board
LEXX ·
Lexaria Bioscience Corp.
replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor
Role change
Nelson Cabatuan
Chief Financial Officer
LEXX ·
Lexaria Bioscience Corp.
Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.
Appointed
Nelson Cabatuan
Chief Financial Officer
LEXX ·
Lexaria Bioscience Corp.
Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.
Role change
Chris Bunka
Principal Financial Officer
LEXX ·
Lexaria Bioscience Corp.
The Company’s Chief Executive Officer, Chris Bunka, will assume the role of principal financial officer at this time.
Departed
Gregory Downey
Chief Financial Officer
LEXX ·
Lexaria Bioscience Corp.
Effective June 6, 2023, Mr. Gregory Downey was dismissed as the Company’s Chief Financial Officer.
Appointed
Catherine C. Turkel
Independent Director
LEXX ·
Lexaria Bioscience Corp.
On September 2, 2022 (the “Effective Date”) the board of directors of Lexaria Bioscience Corp., in accordance with Nevada corporate laws, increased the size of the board to six members and appointed Catherine C. Turkel, PharmD, PhD as an additional independent director to hold such position until the next shareholder’s meeting.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.57 · Most common event other_material